These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 20045200

  • 1. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.
    Aktas O, Kieseier B, Hartung HP.
    Trends Neurosci; 2010 Mar; 33(3):140-52. PubMed ID: 20045200
    [Abstract] [Full Text] [Related]

  • 2. The future of multiple sclerosis treatment.
    Cohen JA.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S55-61. PubMed ID: 19200869
    [Abstract] [Full Text] [Related]

  • 3. Linkage between immunomodulation, neuroprotection and neurogenesis.
    Aharoni R, Arnon R.
    Drug News Perspect; 2009 Feb 01; 22(6):301-12. PubMed ID: 19771319
    [Abstract] [Full Text] [Related]

  • 4. Novel therapeutic options for multiple sclerosis.
    Curtin F, Hartung HP.
    Expert Rev Clin Pharmacol; 2014 Jan 01; 7(1):91-104. PubMed ID: 24325127
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
    Banwell B, Tremlett H.
    Neurology; 2005 Mar 08; 64(5):778-9. PubMed ID: 15753408
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Neuroprotection in the treatment of multiple sclerosis].
    Zipp F, Gold R.
    Nervenarzt; 2011 Aug 08; 82(8):973-7. PubMed ID: 21761185
    [Abstract] [Full Text] [Related]

  • 10. Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.
    Ziemssen T.
    J Neurol; 2005 Nov 08; 252 Suppl 5():v38-45. PubMed ID: 16254701
    [Abstract] [Full Text] [Related]

  • 11. Multiple sclerosis: an immune or neurodegenerative disorder?
    Trapp BD, Nave KA.
    Annu Rev Neurosci; 2008 Nov 08; 31():247-69. PubMed ID: 18558855
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection.
    Neuhaus O, Archelos JJ, Hartung HP.
    Trends Pharmacol Sci; 2003 Mar 08; 24(3):131-8. PubMed ID: 12628358
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Therapeutic strategies in multiple sclerosis: a focus on neuroprotection and repair and relevance to schizophrenia.
    Inglese M, Petracca M.
    Schizophr Res; 2015 Jan 08; 161(1):94-101. PubMed ID: 24893901
    [Abstract] [Full Text] [Related]

  • 20. Getting specific: monoclonal antibodies in multiple sclerosis.
    Lutterotti A, Martin R.
    Lancet Neurol; 2008 Jun 08; 7(6):538-47. PubMed ID: 18485317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.